Wells Fargo analyst Mohit Bansal raised the firm’s price target on Halozyme (HALO) to $60 from $57 and keeps an Equal Weight rating on the shares. The firm notes the company’s Q4 was good, with royalty revenues at $170M vs. $158M consensus. While the company did not update 2025 guidance, Wells thinks there could be upside since Vyvgart launch in CIDP appears to be going well.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Therapeutics: Record Earnings and Future Growth
- Halozyme price target raised to $78 from $73 at Citizens JMP
- Buy Rating Affirmed: Halozyme’s Robust Growth and Strategic Positioning Drive Positive Outlook
- Halozyme price target raised to $72 from $70 at H.C. Wainwright
- Halozyme Therapeutics Achieves Record Revenue in 2024